We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
NUVO - Division of Medical Illumination

Download Mobile App

POC Assay Could Diagnose Acute Coronary Syndrome in 3-5 Minutes

By HospiMedica International staff writers
Posted on 19 Dec 2022
Print article
Image: TruHeart technology aims to prevent heart disease mortality by early point-of-care diagnosis (Photo courtesy of Neuome Peptides)
Image: TruHeart technology aims to prevent heart disease mortality by early point-of-care diagnosis (Photo courtesy of Neuome Peptides)

32% of all global deaths are due to cardiovascular disease (CVD), with 85% of the deaths attributed to heart attack or stroke. This disease state may go undiagnosed due to confusion of symptoms with other medical issues or lack of proper medical attention. Even when discovered, a CVD incident can be too far gone before a heart attack or stroke occurs. There is a need for a preliminary medical test that can be easily taken in any environment that can alert a patient and their medical team to the potential of a cardiac event. Now, a cardiac-specific quantitative test using a finger-prick sample could offer results in 3-5 minutes at the point of care and help in identifying cardiovascular problems anywhere.

Neuome Peptides (Singapore) is in the advanced stages of developing TruHeart, a point of care biomarker assay to diagnose Acute Coronary Syndrome that can give quantifiable results within 3-5 minutes, using a finger-prick sample to test for the crucial biomarkers, Troponins I and T, and Myoglobin (eventually expanding to D-Dimer and Brain Natriuretic Peptide). It is in the advanced stages of R&D and progressing to global clinical trials. It will be submitted for FDA approval and then introduced to the market upon approval. The company’s technology for detecting these biomarkers uses a unique ability to bind at more than one binding site when conjugated with gold nanoparticles.

Such highly sensitive assay platforms can enable early detection of biomarkers even at very low concentration, without needing a laboratory. The test can be used at home, in ambulances, or in emergency rooms, where the results can be acted upon immediately. The product could be a game-changer, allowing patients to affordably screen for this potentially deadly condition conveniently early, in their own home, achieving quantifiable results without needing a laboratory. In comparison to industry standards, it will be uniquely affordable; its peptide-coated cartridges will cost only ~USD 2, while the quantitative electronic reader will cost ~USD 80. This is in contrast to existing point-of-care devices also giving quantitative results for cardiac biomarkers, but at device costs of up to USD 4,500, with cartridges ranging from USD 18-37.

Related Links:
Neuome Peptides

Gold Supplier
12-Channel ECG
Chair Scale
seca 954
Emergency Trolley
Emergency Trolley – 74403
Digital X-Ray Flat Panel Detector

Print article
FIME - Informa



view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: The novel intravascular, catheter-based technology is designed to treat pulmonary hypertension (Photo courtesy of Freepik)

Minimally Invasive Catheter-Based Technology Treats Pulmonary Hypertension

Pulmonary hypertension, a deadly condition impacting roughly 500,000 patients annually across the world, is currently categorized as a rare disease. As it stands, available treatment options are restricted,... Read more

Surgical Techniques

view channel
Image: LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures (Photo courtesy of Microbot Medical)

Tiny Surgical Robot Designed to Streamline Endovascular Interventional Procedures

The endovascular field currently has several unmet needs that can be fulfilled with robotics. However, the current uptake of robotics in this sector is exceptionally low, largely due to several barriers... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.